Newsfile Corp
30 May 2026, 12:36 UTC · 2h ago
Source · https://www.newsfilecorp.com/release/299421/IMMP-CLASS-ACTION-NOTICE-Faruqi-Faruqi-LLP-Reminds-Immutep-IMMP-Investors-of-Securities-Class-Action-Deadline-on-July-6-2026
Read source
Story key points
2 claims · impact-rated
The Independent Data Monitoring Committee recommended the discontinuation of Immutep's TACTI-004 Phase III clinical trial for futility. — The failure of a Phase III trial for a primary efficacy/safety endpoint is a catastrophic event for a biotech company, as evidenced by the 82.6% price collapse mentioned.
-1.00A federal securities class action lawsuit has been filed against Immutep alleging that executives made false or misleading statements regarding the TACTI-004 trial. — Legal proceedings and allegations of fraud create significant contingent liabilities and damage corporate governance credibility.
-0.60Ticker attribution
Model heads
The company is facing a securities class action lawsuit following the discontinuation of a Phase III clinical trial for futility and a subsequent 82.6% drop in share price.
Continue reading
6 related stories
Search tags
The law firm is investigating potential claims on behalf of investors of the company.
The company is mentioned in the context of a securities class action deadline.
The company is mentioned in the context of a securities class action deadline.
No ticker relationship head found.
Impact vectors
3 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
Newsfile Corp
2h ago
